Daiichi Sankyo Company, Limited

Mitsubishi Heavy Industries Thermal Systems, Ltd.

Arqule, Inc.

Masahiro Ota

Hitoshi Ohki

Yoshihiro Shibata

Katsuhiro Kobayashi

Takeshi Jimbo

Takashi Suzuki

Nobuyuki Suzuki

Koichi Nakamura

Masahiro Ikeda

Noriyasu Haginoya

Shinji Matuura

Takayuki Kobayashi

Hideaki Watanabe

Jean-Marc Lapierre

Yasusi Ueda

Tomoharu Tsukada

Miho Hayakawa

Tooru Okayama

Toshiyuki Nakanishi

Yosuke Ando

Manish Tandon

Kiyoshi Nakayama

Yusuke Ota

Craig G Bates

Hidekazu Inoue

Hiroaki Inagaki

Sudharshan Eathiraj

Tomoki Hase

Takayuki Momose

Hideaki Tatenoi

Tomoyuki Tsunemi

Hirotaka Tanabe

Yuichi Tominaga

Takashi Odagiri

Junya Kawai

Daisuke Fukatsu

Akitake Yamaguchi

Keijiro Kobayashi

Tadashi Toki

Kosuke Takeuchi

An air conditioning device for a vehicle includes: a refrigeration cycle including a compressor, a condenser, an expansion valve, and an evaporator through which a refrigerant is sequentially flowed; a high-temperature heat medium circuit through which a high-temperature heat medium has exchanged heat with the refrigerant in the condenser is circulated; a low-temperature heat medium circuit through which a low-temperature heat medium has exchanged heat with the refrigerant in the evaporator is circulated; a connection line connecting the high-temperature heat medium circuit to the low-temperature heat medium circuit; vehicle interior heat exchangers allowed to be introduced the heat medium thereinto; and a switching unit which switches an operation state of the air conditioning device to a first mode allowing to connect the vehicle interior heat exchangers to the high-temperature heat medium circuit, a second mode allowing to connect the vehicle interior heat exchangers to the low-temperature heat medium circuit, or a third mode not allowing to connect the vehicle interior heat exchangers to any one of the high-temperature heat medium circuit and the low-temperature heat medium circuit.

Air conditioning device for vehicle

The present disclosure provides novel compounds or salts thereof, or crystals of the compounds or the salts, which inhibit Axl and are useful in the treatment of a disease caused by hyperfunction of Axl, the treatment of a disease associated with hyperfunction of Axl, and/or the treatment of a disease involving hyperfunction of Axl. The present disclosure provides pyridone derivatives having a tetrahydropyranylmethyl group represented by the following formula (I) having various substituents, or salts thereof, or crystals of the compounds or the salts, wherein R, R, R, R, R, W, X, Y, and Z are each as defined in the specification: 

Pyridone derivatives having tetrahydropyranylmethyl groups

The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of BTK, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.

Amino-pyrrolopyrimidinone compounds and methods of use thereof

Provided is a novel compound or a salt thereof inhibiting MTHFD2 and useful for treating a disease caused by overexpression of MTHFD2, a disease involved in overexpression of MTHFD2 and/or a disease associated with overexpression of MTHFD2. Solution Provided is a sulfonamide derivative having a coumarin skeleton represented by the following formula (I) and having various substituents: wherein R, R, R, R, R, Rand Rare the same as defined in the specification,and a salt thereof.

Sulfonamide derivative having coumarin skeleton

Novel compounds or salts thereof, or crystals thereof, which inhibit Axl and are useful for treating diseases caused by Axl hyperfunction, diseases associated with Axl hyperfunction and/or diseases accompanied by Axl hyperfunction are provided. Pyridone derivatives represented by the formula (1) having various substituents or salts thereof, or crystals thereof (where R, R, R, R, R, A, W, X and n in the formula (1) are as defined in the specification, respectively) are provided.

Pyridone derivatives

A pyrazolopyrimidine compound represented by formula (1) that inhibits the function of HSP90 as a chaperone protein and that has antitumor activity, a medicament comprising a compound represented by formula (1), a pharmaceutical composition comprising a compound represented by formula (1), and a method for treating cancer using a compound represented by formula (1). 

Tricyclic pyrazolopyrimidine derivatives

Growing community of inventors

Tokyo, Japan

Masahiro Ota